WO2012103801A1 - 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 - Google Patents
一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 Download PDFInfo
- Publication number
- WO2012103801A1 WO2012103801A1 PCT/CN2012/070784 CN2012070784W WO2012103801A1 WO 2012103801 A1 WO2012103801 A1 WO 2012103801A1 CN 2012070784 W CN2012070784 W CN 2012070784W WO 2012103801 A1 WO2012103801 A1 WO 2012103801A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- compound
- formula
- preparation
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- compositions of each formulation of the composition before lyophilization is as follows: Formula micafungin sodium trehalose pH adjuster trehalose and micafene number mg / ml mg / ml (pH) net sodium weight ratio
- the formulation with trehalose as a stabilizer especially the weight ratio of trehalose to micafungin sodium is 100:1-1:20, preferably 20: In the case of 1-1:5, it is obviously more stable than the formulation with lactose or maltose as a stabilizer.
- the HPLC analysis of Formulations 1 and 3 is shown in Figures 1-4.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/982,872 US8980827B2 (en) | 2011-01-31 | 2012-01-31 | Medicinal composition containing echinocandin antifungal agent micafungin and preparation method and use thereof |
JP2013552091A JP5723030B2 (ja) | 2011-01-31 | 2012-01-31 | エキノカンジン系抗真菌剤であるミカファンギンを含む薬用組成物およびその製造方法と用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110034055.0A CN102614491B (zh) | 2011-01-31 | 2011-01-31 | 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 |
CN201110034055.0 | 2011-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012103801A1 true WO2012103801A1 (zh) | 2012-08-09 |
Family
ID=46554937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/070784 WO2012103801A1 (zh) | 2011-01-31 | 2012-01-31 | 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8980827B2 (zh) |
JP (1) | JP5723030B2 (zh) |
CN (1) | CN102614491B (zh) |
WO (1) | WO2012103801A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103330932B (zh) * | 2013-04-26 | 2015-12-23 | 江苏豪森药业股份有限公司 | 一种米卡芬净或其盐的药物组合物 |
US10183973B2 (en) | 2014-05-29 | 2019-01-22 | Shanghai Techwell Biopharmaceutical Co., Ltd. | Solvate of cyclic peptide compound, preparation method for same, and uses thereof |
EP3150621A4 (en) * | 2014-05-29 | 2017-12-27 | Shanghai Techwell Biopharmaceutical Co., Ltd | Composition of cyclic peptide compound, preparation method for same, and uses thereof |
EP3240529B1 (en) | 2014-12-31 | 2022-02-02 | Galenicum Health S.L.U. | Stable pharmaceutical compositions comprising micafungin |
CN105106933A (zh) * | 2015-09-06 | 2015-12-02 | 江苏奥赛康药业股份有限公司 | 含米卡芬净的冻干组合物及其制备方法 |
JPWO2017047299A1 (ja) * | 2015-09-15 | 2017-12-21 | 富士フイルム株式会社 | 注射用液剤組成物 |
IN2015MU03858A (zh) * | 2015-10-10 | 2015-10-23 | Gufic Biosciences Ltd | |
WO2017179683A1 (ja) * | 2016-04-15 | 2017-10-19 | Meiji Seikaファルマ株式会社 | ミカファンギンの安定化された医薬組成物 |
FR3095755A1 (fr) * | 2019-05-10 | 2020-11-13 | Balmes Transplantation | Nouveaux médicaments cytoprotecteurs |
CN111044636A (zh) * | 2019-12-30 | 2020-04-21 | 卓和药业集团有限公司 | 米卡芬净含量的分析方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1315865A (zh) * | 1999-07-01 | 2001-10-03 | 藤泽药品工业株式会社 | 冻干形式的稳定的药用组合物 |
CN1345333A (zh) * | 1999-03-03 | 2002-04-17 | 伊莱利利公司 | 棘白菌素/糖类复合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009002481A1 (en) * | 2007-06-26 | 2008-12-31 | Merck & Co., Inc. | Lyophilized anti-fungal composition |
CN102026621A (zh) * | 2008-05-15 | 2011-04-20 | 巴克斯特国际公司 | 稳定的药物制剂 |
-
2011
- 2011-01-31 CN CN201110034055.0A patent/CN102614491B/zh active Active
-
2012
- 2012-01-31 JP JP2013552091A patent/JP5723030B2/ja active Active
- 2012-01-31 WO PCT/CN2012/070784 patent/WO2012103801A1/zh active Application Filing
- 2012-01-31 US US13/982,872 patent/US8980827B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1345333A (zh) * | 1999-03-03 | 2002-04-17 | 伊莱利利公司 | 棘白菌素/糖类复合物 |
CN1315865A (zh) * | 1999-07-01 | 2001-10-03 | 藤泽药品工业株式会社 | 冻干形式的稳定的药用组合物 |
Non-Patent Citations (3)
Title |
---|
CHENG C. C. ET AL.: "Research progress of application of trehalose in medical field", MEDICAL JOURNAL OF QILU, vol. 25, no. 4, August 2010 (2010-08-01), pages 374 - 376 * |
CROWE L. M. ET AL.: "Is trehalose special for preserving dry biomaterials?", BIOPHYSICAL JOURNAL, vol. 71, October 1996 (1996-10-01), pages 2087 - 2093 * |
KAUSHIK J. K. ET AL.: "Why is trehalose an exceptional protein stabilizer?", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 29, July 2003 (2003-07-01), pages 26458 - 26465 * |
Also Published As
Publication number | Publication date |
---|---|
US20130331312A1 (en) | 2013-12-12 |
JP2014507426A (ja) | 2014-03-27 |
CN102614491A (zh) | 2012-08-01 |
US8980827B2 (en) | 2015-03-17 |
JP5723030B2 (ja) | 2015-05-27 |
CN102614491B (zh) | 2014-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012103801A1 (zh) | 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 | |
US9393307B2 (en) | Caspofungin composition | |
JP4972750B2 (ja) | 非経口抗真菌生成物 | |
US9149435B2 (en) | Low impurity content caspofungin preparation, method for preparing same, and use thereof | |
JP5723031B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物 | |
US9149502B2 (en) | Low impurity content caspofungin preparation, method for preparing same, and use thereof | |
EP3013316B1 (en) | Stable intravenous formulation | |
CN101352422B (zh) | 河豚毒素冻干粉针制剂及其制备方法 | |
WO2017185030A1 (en) | Caspofungin formulation with low impurities | |
TWI650133B (zh) | 含有米卡芬淨或其鹽的醫藥組成物 | |
US20230068866A1 (en) | Daptomycin formulation | |
CN101181284A (zh) | 注射用伊曲康唑冻干组合物及制备方法 | |
TWI634897B (zh) | 米卡芬淨或其鹽的醫藥組成物 | |
CN1868471A (zh) | 一种甲基斑蝥胺注射制剂及其制备方法 | |
WO2024088301A1 (zh) | 一种棘白素类似物的药物组合物及其制备方法 | |
CN1611219A (zh) | 左西孟旦药物组合物及其制备方法 | |
TW201302755A (zh) | 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12741746 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013552091 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13982872 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12741746 Country of ref document: EP Kind code of ref document: A1 |